title: [Evodiamine enhances the radiosensitivity of esophageal squamous cell cancer Eca-109 cells].
abstract: Objective To investigate the effect of evodiamine on the radiosensitivity of esophageal squamous cell cancer Eca-109 cells. Methods Eca-109 cells were treated with various concentrations of evodiamine [(10, 20, 40, 60, 80, 100, 120) μg/mL], and then cell proliferation was examined by MTT assay. After the optimal evodiamine concentration was determined, the cells were divided into radiation group (0, 2, 4, 6, 8 Gy X-ray radiation) and radiation combined with evodiamine group (80 μg/mL evodiamine and 0, 2, 4, 6, 8 Gy X-ray radiation) .The radiosensitivity of Eca-109 cells was detected using colony formation assay. Flow cytometry was used to determine cell cycle of Eca-109 cells. The protein expressions of Ku70, Ku80, DNA-PKcs and Rad51 were examined by Western blotting. Results MTT assay showed that evodiamine decreased the proliferation of Eca-109 cells in a concentration-dependent manner. The inhibition reached the maximal level at 80 μg/mL. Compared with radiotherapy alone, the combination of 80 μg/mL evodiamine and radiotherapy improved survival curve and decreased the values of D0 and Dq. Sensitizer enhancement ratio was 1.86±0.06. Furthermore, cell cycle analysis revealed that evodiamine suppressed radiotherapy-induced the G2/M arrest. Additionally, evodiamine treatment also significantly inhibited radiotherapy-induced increase in Ku70, Ku80, DNA-PKcs and Rad51 expressions. Conclusion Evodiamine enhances radiosensitivity of Eca-109 cells during radiotherapy. The effect may be associated with the inhibition of G2/M arrest and the attenuation of Ku70, Ku80, DNA-PKcs and Rad51 expressions.
authors.affiliation: Department of Integrated Chinese and Western Medicine, First Affiliated Hospital, Xinxiang Medical University, Xinxiang 453100, China. *Corresponding author, E-mail: xyfenghui@126.com.
authors.forename: Hui
authors.initials: H
authors.lastname: Feng
authors.affiliation: Department of Integrated Chinese and Western Medicine, First Affiliated Hospital, Xinxiang Medical University, Xinxiang 453100, China.
authors.forename: Baorui
authors.initials: B
authors.lastname: Guo
authors.affiliation: Department of Integrated Chinese and Western Medicine, First Affiliated Hospital, Xinxiang Medical University, Xinxiang 453100, China.
authors.forename: Xiangmei
authors.initials: X
authors.lastname: Kong
authors.affiliation: Department of Integrated Chinese and Western Medicine, First Affiliated Hospital, Xinxiang Medical University, Xinxiang 453100, China.
authors.forename: Biao
authors.initials: B
authors.lastname: Wu
mesh_terms: D015153:Blotting, Western; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects / Q000528:radiation effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects* / Q000528:radiation effects*; D051747:DNA-Activated Protein Kinase / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D004938:Esophageal Neoplasms / Q000378:metabolism / Q000473:pathology; D006801:Humans; D000072200:Ku Autoantigen / Q000378:metabolism; D009687:Nuclear Proteins / Q000378:metabolism; D010936:Plant Extracts / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology*; D051135:Rad51 Recombinase / Q000378:metabolism; D011836:Radiation Tolerance / Q000187:drug effects*; D014965:X-Rays
chemical_list: D009687:Nuclear Proteins; D010936:Plant Extracts; D011799:Quinazolines; C049639:evodiamine; D051747:DNA-Activated Protein Kinase; C497263:PRKDC protein, human; D051135:Rad51 Recombinase; D000072200:Ku Autoantigen